首页> 外文期刊>Cancer Management and Research >Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma
【24h】

Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma

机译:切除的肺腺癌中Cox-2和PD-L1表达的预后价值及其与肿瘤浸润淋巴细胞的关系

获取原文
           

摘要

Programmed cell death-1 ligand 1 (PD-L1), tumor-infiltrating CD8-positive T lymphocytes (CD8-positive TILs), and cyclooxygenase-2 (Cox-2) have been used as prognostic tools in patients with lung adenocarcinoma. We conducted a retrospective review of data from 170 patients who had undergone pulmonary resection as an initial treatment for clinical T1-2 N0 lung adenocarcinoma. We then investigated the expressions of three biomarkers using immunohistochemical analyses and compared the expression levels with the clinicopathological characteristics and outcomes of the patients. Next, we classified the tumors into four groups based on the PD-L1 and CD8-positive TILs statuses and evaluated the prognostic significance of Cox-2 expression according to the tumor immune microenvironment classification. Tumors with positive PD-L1 expression levels had a significantly larger number of CD8-positive TILs than tumors with negative PD-L1 expression levels, whereas tumors with high Cox-2 expressions had significantly fewer CD8-positive TILs than tumors with low Cox-2 expressions. A multivariate analysis showed that histological subtype, nodal metastasis, CD8-positive TILs count, and PD-L1 expression were independent predictors of patient outcome. Using a classification based on the PD-L1 and CD8-positive TILs statuses, the outcomes of patients with a negative PD-L1 expression and a high CD8-positive TIL count were significantly better than those with other classifications. In patients with negative PD-L1 and low CD8-positive TILs, the rate of EGFR mutation was significantly higher than that in other classifications, and Cox-2 expression was a powerful predictor of outcome. Clinical and pathological features in conjunction with the tumor immune microenvironment classification indicate that lung adenocarcinoma should be divided into different subgroups for prognosis and treatment. Classification according to the PD-L1 and CD8-positive TILs statuses might enable the effects of Cox-2 inhibitor to be predicted.
机译:程序性细胞死亡1配体1(PD-L1),肿瘤浸润的CD8阳性T淋巴细胞(CD8阳性TIL)和环氧合酶2(Cox-2)已被用作肺腺癌患者的预后工具。我们对170例作为临床T1-2 N0肺腺癌的初始治疗进行了肺切除的患者进行了回顾性研究。然后,我们使用免疫组织化学分析研究了三种生物标志物的表达,并将表达水平与患者的临床病理特征和预后进行了比较。接下来,我们根据PD-L1和CD8阳性TILs的状态将肿瘤分为四类,并根据肿瘤免疫微环境分类评估Cox-2表达的预后意义。 PD-L1表达水平高的肿瘤的CD8阳性TIL数量明显多于PD-L1表达水平低的肿瘤,而Cox-2表达高的肿瘤CD8阳性TILs明显低于Cox-2低水平的肿瘤表达式。多元分析表明,组织学亚型,淋巴结转移,CD8阳性TILs计数和PD-L1表达是患者预后的独立预测因子。使用基于PD-L1和CD8阳性TILs状态的分类,PD-L1表达阴性和CD8阳性TIL计数高的患者的结局明显优于其他分类。在PD-L1阴性和CD8阳性TIL较低的患者中,EGFR突变的发生率明显高于其他分类,并且Cox-2表达是预后的有力预测指标。临床和病理学特征结合肿瘤免疫微环境分类表明,肺腺癌应分为不同的亚组进行预后和治疗。根据PD-L1和CD8阳性TIL的状态进行分类,可以预测Cox-2抑制剂的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号